Fig. 5

ZON represses CD164 by enhancing miR-506-3p. A Expression of miR-506-3p was measured by qPCR in cervical cancer cells treated with ZON. B Wild type and mutant binding sites of CD164 with miR-506-3p. C, D Cervical cancer cells were treated with miR-506-3p mimic. C Luciferase activity of CD164 was detected by dual luciferase reporter gene assays. D Expression of CD164 was analyzed by qPCR. E Expression of CD164 was determined by Western blot in the cervical cancer cells. The experiments were repeated 3 times, ^**P < 0.01